Terns Pharmaceuticals Inc. has reported triazole compounds acting as gastric inhibitory polypeptide receptor (GIPR) antagonists. They are intended for use in the treatment of diabetes, obesity, liver diseases and cardiometabolic syndrome.
Humanwell Pharmaceutical US Inc. has disclosed prodrugs of somatostatin SST4 receptor agonists described as potentially useful for the treatment of visceral and neuropathic pain.
To address the dual bottlenecks of immunosuppressive cell infiltration and impaired T-cell function in the tumor microenvironment (TME), researchers from the School of Pharmaceutical Sciences of Sun Yat-sen University (China) aimed to develop an engineered bispecific peptide-nanozyme conjugate (BsPNEC) targeting PD-L1 and CXCR1/2.
In a recent paper, researchers from the University of Perugia and University of Naples Federico II have shown how the use of leukemia inhibitory factor receptor (LIFR) antagonists dismantles the pro-CAF programs in pancreatic ductal adenocarcinoma (PDAC) to avoid its progression.
Astrazeneca plc has signed a new strategic collaboration agreement with CSPC Pharmaceutical Group Ltd. to advance the development of next-generation therapies for obesity and type 2 diabetes across eight programs.
Ahead Therapeutics SL has been awarded an Industry Discovery and Development Partnership (IDDP) grant from Breakthrough T1D to support progression of the company’s proprietary Mimi-Top (mimicking tolerogenic particles) platform.
DFNB16, a recessive form of mild-to-moderate human deafness, is caused by mutations in the STRC gene, which encodes stereocilin, a protein essential for the effective function of outer hair cells as cochlear amplifiers. Researchers from the Institut Pasteur and Sorbonne Université in Paris, France, have developed and evaluated the efficacy of an Strc gene therapy in a mouse model of DFNB16.
Formation Bio Inc. and Jiangsu Chia Tai Feng Hai Pharmaceutical Co. Ltd. have announced Formation Bio’s acquisition of worldwide rights, excluding Greater China, to FHND-5032, an oral, small-molecule miR-124 activator being developed for the treatment of autoimmune diseases.
Insilico Medicine Cayman Topco has nominated ISM-0676 as a preclinical candidate targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR).
RSS
